Cargando…
Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers
Primary or acquired therapy resistance is a major obstacle to the effective treatment of cancer. Resistance to apoptosis has long been thought to contribute to therapy resistance. We show here that recombinant TRAIL and CDK9 inhibition cooperate in killing cells derived from a broad range of cancers...
Autores principales: | Montinaro, Antonella, Areso Zubiaur, Itziar, Saggau, Julia, Kretz, Anna-Laura, Ferreira, Rute M. M., Hassan, Omar, Kitzig, Ella, Müller, Ines, El-Bahrawy, Mona A., von Karstedt, Silvia, Kulms, Dagmar, Liccardi, Gianmaria, Lemke, Johannes, Walczak, Henning |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901660/ https://www.ncbi.nlm.nih.gov/pubmed/34535764 http://dx.doi.org/10.1038/s41418-021-00869-x |
Ejemplares similares
-
Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1
por: Lemke, J, et al.
Publicado: (2014) -
The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2
por: Hartwig, Torsten, et al.
Publicado: (2017) -
Anti-Apoptotic NF-κB and “Gain of Function” mutp53 in Concert Act Pro-Apoptotic in Response to UVB+IL-1 via Enhanced TNF Production
por: Müller, Ines, et al.
Publicado: (2015) -
Getting TRAIL back on track for cancer therapy
por: Lemke, J, et al.
Publicado: (2014) -
SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers
por: Jones, Greg G., et al.
Publicado: (2019)